AI주식인사이트AI Stock Insight
B

큐라티스

348080KOSDAQ자연과학 및 공학 연구개발업

62.0 / 100

Reference Date: 2026-04-13

Financial Score26.5 / 40
News Sentiment17.5 / 25
Momentum4.0 / 20
Disclosure14.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 28.6% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Curatis develops vaccines using its platform technology, including QTP101 (tuberculosis prevention), QTP105 (schistosomiasis prevention), and QTP104 (next-generation mRNA-based COVID-19 vaccine). QTP101 has received global Phase 2b/3 trial approval, and the company also provides CMO/CDMO services and open innovation solutions for drug development.

Number of Employees

47people

Average Salary

58.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 120.074.0Point
PBR
2.39Industry Average 3.825.5Point

Lower than industry avg (good)

ROE
-91.68Industry Average -32.113.5Point

2.9x industry avg (excellent)

Debt Ratio
0.06Industry Average 7.528.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲246.8% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲15.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -92.3% (improving, 2yr)

Detailed News Sentiment

2 totalPositive 0Neutral 2Negative 0Average Sentiment Score 70

Detailed Momentum

52-week position3.0Point

52w lower range (24%)

Current 917Won52-week high 1,91152-week low 597
1-month return0.0Point

1m -28.64% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

13 totalPositive 2Neutral 11Negative 0
  • Positive단일판매ㆍ공급계약체결2026-04-08
  • Neutral주식등의대량보유상황보고서(약식)2026-04-06
  • Neutral주식등의대량보유상황보고서(약식)2026-04-06
  • Neutral주식등의대량보유상황보고서(일반)2026-04-02
  • Neutral정기주주총회결과2026-03-31